Radius Helath, Inc. Announces Scientific Presentations At The 40th European Calcified Tissue Society (ECTS) Congress And At The Joint Meeting Of The International Society Of Endocrinology And The Endocrine Society (ICE/ENDO 2014)

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CAMBRIDGE, MA--(Marketwired - May 05, 2014) -

Radius Health Announces Scientific Presentations at the 40th European Calcified Tissue Society (ECTS) Congress and at the joint meeting of the International Society of Endocrinology and the Endocrine Society (ICE/ENDO 2014)

Radius Health, Inc. will present scientific data from studies conducted with abaloparatide (BA058) at the European Calcified Tissue Society (ECTS) Congress, in Prague, Czech Republic, May 17 - 20, 2014. Four abstracts have been accepted for presentation at the Congress.

Abstracts are available on-line at http://www.ectscongress.org/2014/abstractOnline.aspx to registered attendees of the ECTS Congress.

Radius will also present at the joint meeting of the International Society of Endocrinology and the Endocrine Society (ICE/ENDO 2014) in Chicago, Illinois, June 21-24, 2014.

Abstracts are available to view on-line https://endo.confex.com/endo/2014endo/webprogram/programs.html

About Radius Health

Radius Health, Inc. is a science-driven biopharmaceutical company developing novel differentiated therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases. The company’s lead development candidate is abaloparatide (BA058), a bone anabolic for delivery via subcutaneous injection that is currently in Phase 3 development for the reduction of fracture risk in postmenopausal women with severe osteoporosis. The Radius clinical portfolio also includes an abaloparatide transdermal patch for osteoporosis and RAD1901 for estrogen-driven breast cancer brain metastases.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC